Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Interim data presented from phase I/II study of RGX-121

Dec. 19, 2019

Homology reports initial data from phase I/II study of HMI-102 gene therapy in PKU

Dec. 18, 2019

D-amino-acid oxidase inhibitors discovered at SyneuRx International

Dec. 18, 2019

First patient enrolled in pivotal phase III InnovAATe study of Kamada's inhaled AAT

Dec. 17, 2019

BioMarin reports encouraging final phase III data for vosoritide in children with achondroplasia

Dec. 17, 2019

New phase II trial investigates CFZ-533 in pediatric and young adults with type 1 diabetes

Dec. 13, 2019

Xeris reports in-clinic stage data from phase II trial of RTU glucagon

Dec. 11, 2019

Scohia Pharma initiates phase I study of SCO-267

Dec. 11, 2019

Enterovirus contributes to islet autoimmunity

Dec. 11, 2019

Sinovent studies small-molecule human URAT1 inhibitor XNW-3009 in phase I

Dec. 10, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...